Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injection shows promise for stubborn nail infections

NCT ID NCT07311759

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new injection combining a steroid and antifungal drug against a standard topical cream for chronic paronychia, a long-lasting nail fold infection. Twenty-one adults with at least two affected fingernails on their dominant hand will receive both treatments on different fingers to see which works better. The goal is to find a more effective way to control this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triamcinolone acetonide and fluconazole injection
What this could lead to
If successful, this could offer a more effective treatment option for chronic paronychia, potentially reducing the need for long-term topical creams.
What could go wrong
This is a small trial with only 21 participants, so results may not apply to everyone. The injected treatment may cause pain or side effects, and it's unclear if it will be better than standard creams.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 21 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with chronic paronychia affecting ≥ 2 fingernails in the dominant hand. 2. Patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our study 3. Patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our study Exclusion Criteria: 1. Patient with peripheral vascular disease or Raynaud's phenomenon 2. Pregnant and lactating females 3. Patients with autoimmune diseases e.g., connective tissue diseases, psoriasis, reactive arthritis, and pemphigus. 4. Patients with solid or hematological malignancies. 5. Patients on systemic drugs that are known to cause chronic paronychia e.g. retinoids. 6. Patients with any visible focus of infection at the injection site or in the vicinity, including patients with superimposed attack of acute paronychia. 7. Onychomycosis or any associated nail disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic paronychia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cairo University

    Cairo, Egypt